1. Most Discussed
  2. Gainers & Losers
MGZ 1.6¢

EBOLA + MEDIGARD

  1. Stocks78

    2,782 Posts.
    5
    THE Ebola scourge could spell good news for Gold Coast company Medigard (ASX: MGZ) as its blood collection device finally hits the market.

    The fledgling medical instruments developer says sales of the device are expected to start in March with the product gaining exposure in the global medical industry after featuring in the 2014 Sol Millennium Catalogue.

    Medigard last year secured an exclusive licence agreement with Shanghai Sol-Millennium Medical Products Co to manufacture and distribute its Blood Collection Device and Blood Flash Needle.

    Medigard chairman Don Channer told the company’s annual general meeting this week that shareholders and directors “look forward to the rewards” ahead thanks to next year’s sales launch of the device.

    He says feedback from the Blood Collection Device’s recent showing at the Medica trade fair in Germany had been “positive”.

    “Our aspirations of being cheapest and best are being satisfied,” Channer says.

    “All manufacturing machinery has been modified for the change in materials and samples of the new device are being circulated in selected locations in the US, UK and hopefully soon Brazil.

    “Although it has taken us very much longer than expected to arrive at this position, our experience and success in the evolution of the Blood Collection Device has provided a clear pathway for the commercialisation of future products.”

    Medigard says the Blood Collection Device has patents in Australia, the US, Japan, Canada and Europe, while the 3ml vacuum retractable syringe has patents in South Africa, the US, Australia, China, Japan and Canada.

    “The Blood Flash Needle which will be the next focus for the company and Sol Millennium has granted patents in Australia, South Africa and Europe,” says Channer.

    “With the incidence of such terrible epidemics as Ebola, the need for safety medical devices is increasing.

    “We believe the company and Sol Millennium will be well placed to help satisfy this need.”

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.


HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.